Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancer.

摘要: One of the primary challenges in treatment patients with early-stage breast cancer is determining which will benefit from adjuvant chemotherapy. Traditionally, decisions have been made based on a combination tumor characteristics and patient physician perspectives regarding risks benefits. Recent technologic advances, including development gene-expression arrays, led to identification molecular signatures that provide prognostic information addition basic clinicopathologic features individual tumors. While these new methods allow for more refined determination prognosis an patient, few data are available support use technologies clinic decision-making. At present, single retrospective study one assay, 21-gene recurrence score, decision-making Large, multinational clinical trials currently ongoing evaluate two multiparameter assays, although it be many years before oncologists can apply results clinic.